Galunisertib demonstrates the ability to inhibit TGFβ-dependent tumor cell intrinsic and extrinsic functions in vitro and in vivo, and to inhibit tumor-cell growth in established tumor mouse models (Yingling et al., [25]). The gene discussed is TGFB1; the disease is neoplasm.